Replies to post #23385 on The Rising Influence of Rising Affluence

[DewDiligence]

ABT 4Q20 Results by Business Segment

  
                  %Corp      YoY Growth   
 Segment          Sales   (const currency)   
 Medical devices*  30%       flat 
 Diagnostics       41%      +109% 
 Nutrition         18%        +4% 
 Drugs†            11%        +3% 

61% of overall sales were ex-US.

*Includes diabetes care.
†Branded generics in emerging markets.

[DewDiligence]

ABT at all-time high. The company's 2020 performance and 2021 guidance are simply astonishing.

ABT expects $6.5-7B of 2021 COVID-19 diagnostic revenue.

[DewDiligence]

ABT _sold_$2.2B_of_COVID-19_diagnostics_in_1Q21 (down from $2.4B in 4Q20):

https://abbott.mediaroom.com/2021-04-20-Abbott-Reports-First-Quarter-2021-Results

Non-GAAP EPS guidance for 2021 remains >=$5.00 (+37%, or more, relative to 2020).

1Q21 one-page graphic:
https://www.abbottinvestor.com/static-files/f172ced6-f814-490b-8e5c-3be152119058